The National Institutes of Health of Mexico will follow the protocol Phase 3 of the candidate treatment VIR-7831 which has the potential to neutralize the virus, feed the infected cells and create one protection barrier in the pulmonaries of patients with high risk of complicating ante covid-19 by having diabetes, hypertension, obesity and other pathologies, or well to be mayor of 55 years of age.
Sigfrido Rangel, medical director of GSK México, explanation and MILENIO which monoclonal anticircle against SARS-CoV-2 Avoid getting patients complicated by having chronic and degenerative diseases controlled or uncontrolled, and increased by the degree of intubation due to the low oxygen saturation in blood, high degree of inflammation and infection in the pulmonaries.
“The monoclonal antibody attacks the SARS-CoV-2 protein spike and prevents the infection from progressing and adhering to the cells that kill those rodents in the lung,” he explained.
How does it work?
El biotechnology is injected into the vein for 60 to 90 minutes (at the time when an antibiotic is taken) and the SARS-CoV-2 protein S block is mediated and other receptors that lesion the pulmonary. In addition, the monoclonal antecedent has the peculiarity of elevating the patient’s immunological response in order to be able to fight with its white globules that are infected.
El anticuerpo monoclonal, developed by GSK and the company Vir, will be summoned to persons who have been in contact with any positive person or well that they present the first symptoms of having acquired covid-19, inclusive, the new variant detected by Reino Unido.
Se debe de sum up in a maximum of 10 days to have ten the first sins and with it avoids the day that causes the coronavirus to decrease respiratory capacity, saturation levels, pulmonary inflammation and infection, the collapse of the rest of vital organs.
Detailing that the effect is not that of a vacancy, that one as a final generates immunity to large space. If a treatment is taken, as is the case with any consultation, with the benefit of the person receiving the injection by intravenous live the active substances are concentrated in the pulmon to block the covid-19 virus, including ‘o other pathogens of the coronavirus family.
Also, prevent the virus from replicating and infecting other high-risk patient cells to treat diabetes, hypertension, obesity, renal failure, whether or not they are well controlled.
“In these 10 days, the virus itself is replicating itself and it is essential that it does not reach this limit in order to protect itself,” he said.
The treatment is useful for patients such as the President Andrés Manuel López Obrador, which has signs and symptoms, has uncontrolled hypertension, “with a single dose that is called a protective protector”.
When will you test the samples?
The investigation of VIR-7831 (also known as GSK4182136) was carried out in more than 1 mile 30 outpatient participants all over the world, from February, will continue with its Phase 3 Mexican Patient Examination Clinic law to obtain the authorization of part of the Federal Commission for the Protection against Sanitary Risks (Cofepris).
“We are recruiting ambulatory patients with risk factors and symptoms,” he said.
In February, the Phase 3 clinical study will be held, and it is hoped that the results will be available in April and count towards the authorization of treatment in May 2021.
‘We are a deadly virus. VIR-7831 is an antidote with characteristics that can prevent hospitalization and death through multiple mechanisms “, also George Scangos, Ph.D., executive director of Vir, socio en el desarrollo.
The first Clinical studies completed in United Kingdom and San Francisco, United Statess, only alert to minor allergic reactions. It is not limited to minor editions or embarrassments.
The VIR-7831 clinical development program includes other additional tests that may, in fact, involve intubated patients in order to elevate their immunological system.
The Independent Data Monitoring Committee recommends on 30 September 2020 that the continuous study in Phase 3 be based on a positive evaluation of the security and tolerability dates of the initial phase of Phase 2, “if there is an exit, the VIR -7831 has the potential to advance in covid-19 ”outpatient treatment.
icc